immunotherapy

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose...

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer...

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort...

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with...

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

 Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T...

Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences

Breakthrough Spatial Biology Solutions Accelerate Immuno-Oncology (IO) Drug Discovery and Development BETHESDA, Md., Nov. 6, 2024 /PRNewswire/ -- Precision for...

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable...

error: Content is protected !!